Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of REGN13335 in Healthy Adults
NCT06137482Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2023
- Primary completion
- Feb 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of regn13335 in pulmonary arterial hypertension (PAH) (8 cohorts), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Incidence of treatment emergent adverse events at Day 113 and Severity of treatment emergent adverse events at Day 113. Started Dec 2023; status: completed.
02
Drugs
regn13335
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT06137482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06137482.